$5.920
-0.118 (-1.99%)At close
ABEO News
ABEO Events
Abeona Therapeutics Q2 Revenue at $11.38M
Reports Q2 revenue $11.38M, consensus $12.16M. "Our confidence in ZEVASKYN's substantial opportunity is reinforced by our launch progress and experience to date as we engage with a growing number of patients and expand our QTC network," said Vish Seshadri, Chief Executive Officer of Abeona Therapeutics. "As early real-world experience with ZEVASKYN matures across activated sites, we expect to drive broader adoption and long-term growth."
Abeona Announces Cincinnati Children's as Seventh Qualified Treatment Center for Zevaskyn
Abeona Therapeutics announced the activation of Cincinnati Children's as the seventh Qualified Treatment Center for the administration of Zevaskyn. Zevaskyn is an autologous gene-modified cellular sheet therapy indicated for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa. "Cincinnati Children's is one of largest EB centers in the US and we are thrilled to announce its activation as a ZEVASKYN QTC. We look forward to collaborating with Cincinnati Children's to make ZEVASKYN available to RDEB patients in need," said Madhav Vasanthavada, chief commercial officer of Abeona.
Abeona Therapeutics Q1 Revenue at $8.72M
Reports Q1 revenue $8.72M, consensus $4.94M. "We are excited that an increasing number of patients at our QTCs are getting scheduled for ZEVASKYN slots this quarter," said Vish Seshadri, president and CEO of Abeona Therapeutics. "We're encouraged by the recent acceleration of onboarding efforts of QTCs to activate, so they can begin to treat patients with ZEVASKYN."
2025 Revenue of $5.8M Exceeds Consensus
Reports 2025 revenue $5.8M, consensus $4.82M. "2026 is about building a steady cadence of biopsies and treatments," said CEO Vish Seshadri. "We are focused on ensuring every ZEVASKYN patient has a seamless experience throughout their treatment journey. Establishing these commercial foundations will position us to scale-up ZEVASKYN in 2026 and beyond."
Abeona Therapeutics Updates on Zevaskyn Launch Progress
Abeona Therapeutics announced an update on the building momentum in the Company's launch of FDA-approved Zevaskyn, a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa, RDEB. Following the optimization of a release assay in 2025, Zevaskyn commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with Zevaskyn, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。